🇺🇸 FDA
Pipeline program

Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

18870

Phase 2 small_molecule active

Quick answer

Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg for Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials